Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Ogbuagu O, Goldman JD, Gottlieb RL, Singh U, Shinkai M, Acloque G, Fusco DN, Gonzalez E, Kumar P, Luetkemeyer A, Lichtman A, Mozaffarian A, Koullias Y, Hyland RH, Llewellyn J, Osinusi A, Duff F, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Nadig P, Kohli A; OAKTREE Trial Investigators.
Ogbuagu O, et al. Among authors: gottlieb rl.
Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00238-5. doi: 10.1016/S1473-3099(25)00238-5. Online ahead of print.
Lancet Infect Dis. 2025.
PMID: 40675167